In another phase 1 trial, there was an association between vaccination dose, the immunization schedule, and the prevalence of HER2-specific humoral responses after administration of recombinant HER2 protein with adjuvant AS15 in trastuzumab-naive patients with stage II-III HER2+ breast cancer that had undergone surgical resection and adjuvant therapy (79). This evidence concerns the gene ERBB2 and breast cancer.